Allspring Global Investments Holdings LLC Takes $4.15 Million Position in Twist Bioscience Co. (NASDAQ:TWST)

Allspring Global Investments Holdings LLC acquired a new stake in Twist Bioscience Co. (NASDAQ:TWST - Free Report) during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm acquired 84,205 shares of the company's stock, valued at approximately $4,150,000. Allspring Global Investments Holdings LLC owned approximately 0.14% of Twist Bioscience as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Calamos Advisors LLC acquired a new stake in shares of Twist Bioscience in the 2nd quarter valued at approximately $281,000. EdgeRock Capital LLC acquired a new stake in Twist Bioscience in the second quarter valued at approximately $43,000. Nisa Investment Advisors LLC grew its stake in shares of Twist Bioscience by 31.3% during the second quarter. Nisa Investment Advisors LLC now owns 2,288 shares of the company's stock worth $113,000 after buying an additional 546 shares during the last quarter. Blue Trust Inc. increased its holdings in shares of Twist Bioscience by 2,912.8% during the second quarter. Blue Trust Inc. now owns 1,175 shares of the company's stock worth $58,000 after buying an additional 1,136 shares in the last quarter. Finally, QRG Capital Management Inc. lifted its stake in shares of Twist Bioscience by 9.1% in the 2nd quarter. QRG Capital Management Inc. now owns 59,443 shares of the company's stock valued at $2,929,000 after acquiring an additional 4,981 shares during the last quarter.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on the company. Barclays lowered their target price on Twist Bioscience from $60.00 to $55.00 and set an "overweight" rating for the company in a report on Monday, August 5th. The Goldman Sachs Group lifted their target price on shares of Twist Bioscience from $45.00 to $55.00 and gave the stock a "buy" rating in a research report on Tuesday, July 9th. Scotiabank boosted their target price on shares of Twist Bioscience from $43.00 to $48.00 and gave the stock a "sector outperform" rating in a report on Monday, May 6th. Robert W. Baird raised their price target on shares of Twist Bioscience from $40.00 to $46.00 and gave the company an "outperform" rating in a research note on Monday, August 5th. Finally, JPMorgan Chase & Co. boosted their price objective on shares of Twist Bioscience from $28.00 to $35.00 and gave the stock an "underweight" rating in a research note on Monday, August 5th. One investment analyst has rated the stock with a sell rating and eight have issued a buy rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $48.22.

Insider Transactions at Twist Bioscience

In other Twist Bioscience news, insider Dennis Cho sold 709 shares of Twist Bioscience stock in a transaction on Monday, August 5th. The shares were sold at an average price of $39.93, for a total value of $28,310.37. Following the completion of the sale, the insider now directly owns 78,996 shares of the company's stock, valued at $3,154,310.28. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. In other Twist Bioscience news, insider Dennis Cho sold 709 shares of the firm's stock in a transaction that occurred on Monday, August 5th. The stock was sold at an average price of $39.93, for a total value of $28,310.37. Following the completion of the sale, the insider now owns 78,996 shares of the company's stock, valued at $3,154,310.28. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Paula Green sold 918 shares of the company's stock in a transaction that occurred on Thursday, June 6th. The stock was sold at an average price of $51.33, for a total value of $47,120.94. Following the transaction, the senior vice president now directly owns 90,593 shares in the company, valued at $4,650,138.69. The disclosure for this sale can be found here. Insiders sold a total of 21,327 shares of company stock valued at $978,760 in the last quarter. 3.92% of the stock is currently owned by company insiders.

Twist Bioscience Trading Down 3.7 %

TWST stock traded down $1.66 during midday trading on Monday, hitting $43.24. The stock had a trading volume of 1,057,800 shares, compared to its average volume of 808,389. The firm has a market cap of $2.53 billion, a P/E ratio of -12.87 and a beta of 1.76. The business has a fifty day moving average price of $48.89 and a two-hundred day moving average price of $42.68. Twist Bioscience Co. has a 1-year low of $14.42 and a 1-year high of $60.90.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last announced its quarterly earnings data on Friday, August 2nd. The company reported ($1.47) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.76) by ($0.71). The business had revenue of $81.50 million during the quarter, compared to analyst estimates of $77.40 million. Twist Bioscience had a negative net margin of 74.63% and a negative return on equity of 32.17%. The firm's revenue for the quarter was up 27.7% compared to the same quarter last year. During the same period in the prior year, the firm earned ($1.01) earnings per share. On average, equities analysts anticipate that Twist Bioscience Co. will post -3.13 EPS for the current year.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.